Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on September 2022

Classification of products:

Status	Description
GREEN	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
AMB 1	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
AMB 2	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
AMB SCP	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
RED	Red-Hospital initiation and continuation only
GREY	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
PURPLE	To be supplied from the appropriate commissioned provider.
NR	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
Nil				
2) New Requests				
Faricimab (TA799, TA800)	RED			The formulary will reflect the TAG – ICS is the responsible commissioner. Capacity issues within ophthalmology
Romosozumab (TA721)	RED			The formulary will reflect the TAG – ICS is the responsible commissioner.

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Ranibuzimab biosimilar	RED			The formulary will reflect the TAG – ICS is the responsible commissioner. Capacity issues within ophthalmology will restrict switching.
3) New formulations & extensions to use				
Risperidone LA Depot injection (Okedi)	AMB 1 H/ERY			AMB SCP - NEL/NL Request from HFT to use 2 weekly preparation – cost neutral
Paliperidone LA Depot injection (Byannli)	AMB 1 H/ERY			AMB SCP - NEL/NL Request from HFT to use 6 monthly preparation – cost neutral
4) Products considered by NICE				
TA792 Filgotinib for treating moderately to severely active ulcerative colitis	RED			The formulary will reflect the TAG – ICS is the responsible commissioner.
TA794 Diroximel fumarate for treating relapsing–remitting multiple sclerosis	RED			The formulary will reflect the TAG – NHSE is the responsible commissioner.
TA788: Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy	RED			The formulary will reflect the TAG – NHSE is the responsible commissioner.
TA789: Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations	RED			The formulary will reflect the TAG – NHSE is the responsible commissioner.
TA796 Venetoclax for treating chronic lymphocytic leukaemia	RED			The formulary will reflect the TAG – NHSE is the responsible commissioner.
TA798 Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation	RED			The formulary will reflect the TAG – NHSE is the responsible commissioner.

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA801 Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer	RED			The formulary will reflect the TAG – NHSE is the responsible commissioner.
TA802 Cemiplimab for treating advanced cutaneous squamous cell carcinoma	RED			The formulary will reflect the TAG – NHSE is the responsible commissioner.
5) Appeals against earlier decisions by the APC				
None				
6) Miscellaneous formulary decisions by the APC				
Phytomenadione and menadiol	AMB 1			Previously missed at NLAPC classification document

The following guidelines were presented to and approved at the September 2022 meeting of the APC:

- None this month

The following Green+ drug information leaflets were presented to and approved at the September 2022 meeting of the APC:

- Nil

The following shared care guidelines were presented to and approved at the September 2022 meeting of the APC:

- None this month

Other documents presented to and approved at the September 2022 meeting of the APC:

- None this month